Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Mar 30, 2021 · 10-K · 89 days after period end · 0001104659-21-044010
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|
| Net Income | -$8.04M | -$2.30K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 30, 2021 · 89 d after period end
